Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

927 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The demise of multidrug-resistant HIV-1: the national time trend in Portugal.
Vercauteren J, Theys K, Carvalho AP, Valadas E, Duque LM, Teófilo E, Faria T, Faria D, Vera J, Aguas MJ, Peres S, Mansinho K, Vandamme AM, Camacho RJ; Portuguese HIV-1 Resistance Study Group. Vercauteren J, et al. Among authors: vera j. J Antimicrob Chemother. 2013 Apr;68(4):911-4. doi: 10.1093/jac/dks470. Epub 2012 Dec 9. J Antimicrob Chemother. 2013. PMID: 23228933 Free PMC article.
HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen.
Cavaco-Silva J, Abecasis A, Miranda AC, Poças J, Narciso J, Águas MJ, Maltez F, Almeida I, Germano I, Diniz A, Gonçalves Mde F, Gomes P, Cunha C, Camacho RJ; Portuguese HIV-2 Resistance Study Group. Cavaco-Silva J, et al. PLoS One. 2014 Mar 28;9(3):e92747. doi: 10.1371/journal.pone.0092747. eCollection 2014. PLoS One. 2014. PMID: 24681625 Free PMC article.
Development of the HIV360 international core set of outcome measures for adults living with HIV: A consensus process.
Marques-Gomes J, Salt MJ, Pereira-Neto R, Barteldes FS, Gouveia-Barros V, Carvalho A, d'Arminio-Monforte A, De-la-Torre-Rosas A, Harris A, Esteves C, Maor C, Mora C, Oliveira C, Sousa C, Richman DD, Martinez E, Cota-Medeiros F, Gramacho F, Behrens GMN, Gonçalves G, Farinha H, Nabais I, Vaz-Pinto I, Sierra-Madero J, Sousa-Gago J, Thornhill J, Vera J, Erceg-Tusek M, Tavares M, Vasconcelos M, Fernandes N, Gianotti N, Langebeek N, Anjos P, Couto R, Fernandes R, Rajasuriar R, Serrão R, Watson S, Branco T, Teixeira T, Soriano V. Marques-Gomes J, et al. Among authors: vera j. HIV Med. 2022 Jul;23(6):639-649. doi: 10.1111/hiv.13221. Epub 2021 Dec 28. HIV Med. 2022. PMID: 34964226 Review.
Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial.
Phillips AN, Carr A, Neuhaus J, Visnegarwala F, Prineas R, Burman WJ, Williams I, Drummond F, Duprez D, Belloso WH, Goebel FD, Grund B, Hatzakis A, Vera J, Lundgren JD. Phillips AN, et al. Among authors: vera j. Antivir Ther. 2008;13(2):177-87. doi: 10.1177/135965350801300215. Antivir Ther. 2008. PMID: 18505169 Clinical Trial.
Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations.
Youle M, Staszweski S, Clotet B, Arribas JR, Blaxhult A, Carosi G, Dejesus E, Di Perri G, Estrada V, Fisher M, Kovacs C, Kulasegaram R, Lazzarin A, Marriott D, Muñoz L, Reynes J, Shalit P, Slim J, Tsoukas C, Vaccaro A, Vera J. Youle M, et al. Among authors: vera j. HIV Clin Trials. 2006 Mar-Apr;7(2):86-96. doi: 10.1310/2xvk-pbgl-735n-wh72. HIV Clin Trials. 2006. PMID: 16798623
927 results